News Release Archive http://pfizer.mediaroom.com/ Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector http://pfizer.mediaroom.com/index.php?s=5149&item=22822 MADISON, N.J., Dec. 29, 2010 /PRNewswire-FirstCall/ -- Pfizer Animal Health today announced an agreement to acquire Synbiotics Corporation (Pink Sheets: SYNB), a privately held, Kansas City-based leader in the development, manufacture and marketing of immunodiagnostic tests for companion and food production animals. Wed, 29 Dec 2010 12:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=22822 Newly Published Investigational Apixaban ADVANCE-3 Study Results Demonstrate Statistical Superiority to Enoxaparin with Comparable Rates of Bleeding in the Prevention of Venous Thromboembolism Following Total Hip Replacement Surgery http://pfizer.mediaroom.com/index.php?s=5149&item=22714 PRINCETON, N.J. and NEW YORK, Dec. 22, 2010 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. Wed, 22 Dec 2010 17:25:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=22714 Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older http://pfizer.mediaroom.com/index.php?s=5149&item=22713 NEW YORK, Dec. Wed, 22 Dec 2010 14:43:02 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=22713 Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc. http://pfizer.mediaroom.com/index.php?s=5149&item=22617   NEW YORK, Dec. 15, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. Wed, 15 Dec 2010 17:01:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=22617 Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc. http://pfizer.mediaroom.com/index.php?s=5149&item=22619 NEW YORK, Dec. 15, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. Wed, 15 Dec 2010 17:01:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=22619 Pfizer Declares A 20-Cent First-Quarter 2011 Dividend http://pfizer.mediaroom.com/index.php?s=5149&item=22475 NEW YORK, Dec. 13, 2010 /PRNewswire-FirstCall/ -- The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent first-quarter 2011 dividend on the company's common stock, payable March 1, 2011, to shareholders of record at the close of business on February 4, 2011.  Pfizer increased the dividend by approximately 11 percent, to 20 cents from 18 cents per share. Mon, 13 Dec 2010 16:32:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=22475 Pfizer Board of Directors Elects George A. Lorch Non-Executive Chairman http://pfizer.mediaroom.com/index.php?s=5149&item=22474 NEW YORK, Dec. 13, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the Company's Board of Directors has elected George A. Lorch, 68, who has served as an independent director since 2000, as non-executive Chairman of the Board, effective immediately. Mon, 13 Dec 2010 16:30:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=22474 Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine http://pfizer.mediaroom.com/index.php?s=5149&item=22394 NEW YORK, Dec. 12, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today. Sun, 12 Dec 2010 05:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=22394 Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety http://pfizer.mediaroom.com/index.php?s=5149&item=22387 NEW YORK, Dec. 10, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia).  In addition, Pfizer is discontinuing clinical studies of Thelin worldwide. Fri, 10 Dec 2010 08:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=22387 Angie Harmon and Children's Advil® Invite Families to Sing Away the Cold and Flu Season Blues http://pfizer.mediaroom.com/index.php?s=5149&item=20713 MADISON, N.J., Dec. 7, 2010 /PRNewswire-FirstCall/ -- At the height of this year's cold and flu season, Angie Harmon, mom of three, is teaming up with the makers of Children's Advil® to launch "Relieve My Fever" -- a contest that invites parents and their kids to sing the Children's Advil® rendition of the classic song "Fever" for a chance to win $15,000. Tue, 07 Dec 2010 10:06:57 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20713 National Initiative Urges 10 Million At-Risk Boomers to 'Face Alzheimer's' http://pfizer.mediaroom.com/index.php?s=5149&item=20687 CHICAGO and NEW YORK, Dec. 6, 2010 /PRNewswire/ -- With as many as 10 million U.S. baby boomers at risk for developing Alzheimer's,(1) the Alzheimer's Association and Pfizer (NYSE: PFE) are collaborating to help raise awareness of Alzheimer's disease by emphasizing to all Americans, "It's Time to Face Alzheimer's. Mon, 06 Dec 2010 12:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20687 Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia http://pfizer.mediaroom.com/index.php?s=5149&item=20683 NEW YORK, Dec. 6, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002). Mon, 06 Dec 2010 08:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20683 Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer http://pfizer.mediaroom.com/index.php?s=5149&item=20608 NEW YORK, Dec. 5, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has elected Ian C. Read, 57, currently head of the Company's global biopharmaceutical operations, as President, Chief Executive Officer and Director. Sun, 05 Dec 2010 20:09:20 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20608 Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia http://pfizer.mediaroom.com/index.php?s=5149&item=20501 NEW YORK, Dec. 3, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients.  These regulatory submissions are planned for 2011. Fri, 03 Dec 2010 17:01:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20501 Centrum® and Molly Shannon Search for 'America's Most Amazingly Energized Woman' This Holiday Season http://pfizer.mediaroom.com/index.php?s=5149&item=20467 MADISON, N.J., Dec. 2, 2010 /PRNewswire/ -- Getting it all done while enjoying life takes the right attitude and energy. Thu, 02 Dec 2010 09:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20467 SUTENT® Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET) http://pfizer.mediaroom.com/index.php?s=5149&item=20459 NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved SUTENT® (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults. Experience with SUTENT as initial treatment is limited in this disease. Thu, 02 Dec 2010 06:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20459 Caltrate® Soft Chews Offer A New and Delicious Way to Help Americans Reach Their Recommended Daily Calcium and Vitamin D Intake http://pfizer.mediaroom.com/index.php?s=5149&item=20420 MADISON, N.J., Nov. 30, 2010 /PRNewswire/ -- On the heels of the Institute of Medicine increasing the daily recommended intake of vitamin D to maintain bone health, Americans may be left wondering how to meet the new guidelines. Tue, 30 Nov 2010 00:02:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20420 Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology http://pfizer.mediaroom.com/index.php?s=5149&item=20337 NEW YORK, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Pfizer (NYSE: PFE) said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7. Mon, 29 Nov 2010 08:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20337 Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease http://pfizer.mediaroom.com/index.php?s=5149&item=20336 NEW YORK and CARMIEL, Israel, Nov. 29, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX, TASE: PLX) today announced the submission of a Marketing Authorization Application to the European Medicines Agency for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD)for the treatment of Gaucher disease. Mon, 29 Nov 2010 02:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20336 Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc. http://pfizer.mediaroom.com/index.php?s=5149&item=20089 NEW YORK, Nov. 22, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. Mon, 22 Nov 2010 08:15:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=20089 Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC) http://pfizer.mediaroom.com/index.php?s=5149&item=19882 NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. Fri, 19 Nov 2010 07:55:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=19882 APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued http://pfizer.mediaroom.com/index.php?s=5149&item=19888 PRINCETON, N.J. & NEW YORK -- NOVEMBER 18, 2010 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy. Thu, 18 Nov 2010 18:17:10 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=19888 Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds http://pfizer.mediaroom.com/index.php?s=5149&item=19580 MADISON, N.J., Nov. 16, 2010 /PRNewswire/ -- From crowded malls to stuffy noses, consumers are in need of relief, especially during the hectic holiday season. Tue, 16 Nov 2010 10:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=19580 Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco http://pfizer.mediaroom.com/index.php?s=5149&item=19573 NEW YORK, Nov. 16, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) today announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers. Tue, 16 Nov 2010 08:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=19573 Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows http://pfizer.mediaroom.com/index.php?s=5149&item=19567 CHICAGO, Nov. 14, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. Sun, 14 Nov 2010 09:00:00 -0500 http://pfizer.mediaroom.com/index.php?s=5149&item=19567